Artemisia absinthium L. (Wormwood) Extract Effect on 3,4-Methylenedioxymethamphetamine Withdrawal in Rats: An Animal Study

Document Type : Original Article

Authors

1 Neuroscience Research Center, Institute of Neuropharmacology, Department of Traditional Medicine, Faculty of Persian Medicine, Kerman University of Medical Sciences, Kerman, Iran

2 Neurology Research Center, Institute of Neuropharmacology, Department of Neurology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran

3 Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran

4 Herbal and Traditional Medicines Research Center, Department of Traditional Pharmacy, Faculty of Persian Medicine, Kerman University of Medical Sciences, Kerman, Iran

5 Modeling in Health Research Center, Institute for Futures Studies in Health, Department of Biostatistics and Epidemiology, Faculty of Public Health, Kerman University of Medical Sciences, Kerman, Iran

10.34172/ahj.1578

Abstract

Background: Methamphetamine is a common addictive industrial substance. Medicinal plants such as Artemisia absinthium L. with anti-inflammatory, antioxidant, analgesic, neuroprotective, antidepressant, and antipyretic properties may help patients reduce withdrawal syndrome symptoms.
Methods: Five treatment groups received intraperitoneal (i.p.) injections of 3,4-methylenedioxymethamphetamine (MDMA) and an ethanolic extract of A. absinthium diluted in 0.9% normal saline for 7 days. The animals were assigned to five groups: Group I (Control): NaCl 0.9% + Naloxone (SN), administered daily via intraperitoneal (i.p.) injection; Group II: MDMA + NaCl 0.9% + Naloxone (MSN), administered daily via i.p. injection; Groups III, IV, and V: MDMA + NaCl 0.9% + Naloxone + ethanolic Artemisia absinthium extract at concentrations of 5%, 10%, and 25% (MSNA), respectively, administered daily via i.p. injection. To induce withdrawal syndrome, two hours after the last injection of MDMA on the 7th day, naloxone was injected (i.p.) at a dose of 1 mg/kg, and rats were quickly transferred to glass cylinders, and the symptoms of MDMA withdrawal syndrome based on stomach cramp, diarrhea, bruxism, body dragging, and wet dog shakes were recorded within 30 minutes.
Findings: The MSN and MSNA 5% interventions may not be well-tolerated and could require reevaluation to minimize adverse effects; however, MSNA 10% and MSNA 25% showed reduced severity, suggesting potential for better tolerability and effectiveness in managing symptoms like writhing, body dragging, teeth chattering, and diarrhea.
Conclusion: It appears that 10% and 25% ethanolic extracts of A. absinthium can lessen certain behavioral signs associated with animal addiction withdrawal. We need more research to optimize dosages for better results.

Highlights

 Rostam Seifadini(Google Scholar)(Pubmed)

Keywords

References

  1. Paknahad S, Akhgari M, Ghadipasha M. An alarming rise in the prevalence of deaths with methamphetamine involved in Tehran, Iran 2011-2018. Forensic Sci Med Pathol. 2021;17(2):208-15. doi: 10.1007/s12024-020-00339-9.
  2. Pirnia B, Pirnia K, Aghajanpoor M, Mardan F, Zahiroddin A. Relationship between function of hypothalamic-pituitary-adrenal axis and executive functions in chronic methamphetamine users: a cross-sectional study. Asian J Psychiatr. 2018;35:113-4. doi: 10.1016/j.ajp.2018.05.001.
  3. Jones CM, Houry D, Han B, Baldwin G, Vivolo-Kantor A, Compton WM. Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction. Ann N Y Acad Sci. 2022;1508(1):3-22. doi: 10.1111/nyas.14688.
  4. Cumming C, Kinner SA, McKetin R, Young JT, Li I, Preen DB. The predictive validity of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) for moderate- to high-risk cannabis, methamphetamine and opioid use after release from prison. Addiction. 2023;118(6):1107-15. doi: 10.1111/ add.16138.
  5. Citaristi I. United Nations Office on Drugs and Crime— UNODC. In: The Europa Directory of International Organizations 2022. Routledge; 2022. p. 248-52.
  6. Čechová B, Šlamberová R. Methamphetamine, neurotransmitters and neurodevelopment. Physiol Res. 2021;70(S3):S301-15. doi: 10.33549/physiolres.934821.
  7. Ru Q, Xiong Q, Zhou M, Chen L, Tian X, Xiao H, et al. Withdrawal from chronic treatment with methamphetamine induces anxiety and depression-like behavior in mice. Psychiatry Res. 2019;271:476-83. doi: 10.1016/j. psychres.2018.11.072.
  8. Modarresi A, Eslami K, Kouti L, Hassanvand R, Javadi M, Sayyah M. Amantadine reduces persistent fatigue during post-acute withdrawal phase in methamphetamine abstained individuals: a randomized placebo-controlled trial. J Subst Use. 2018;23(6):584-90. doi: 10.1080/14659891.2018.1459904.
  9. Guerin AA, Bridson T, Plapp HM, Bedi G. A systematic review and meta-analysis of health, functional, and cognitive outcomes in young people who use methamphetamine. Neurosci Biobehav Rev. 2023;153:105380. doi: 10.1016/j. neubiorev.2023.105380.
  10. Duval CJ, Balkchyan AA, Sarkisyan A, Pedersen ER, Nagata JM, Keshishian T, et al. Methamphetamine use and disordered eating: a case study of an understudied phenomenon. Eat Weight Disord. 2022;27(7):2947-51. doi: 10.1007/s40519- 022-01380-z.
  11. Topcuoğlu M, Erdoğan A, Kulaksızoğlu B. Dermatosis due to methamphetamine use: a case report. Addicta Turk J Addict. 2021;8(2):157-9. doi: 10.5152/addicta.2021.20042.
  12. Buddam A, Vellanki M, Chandra S, Rangray R. S1723 Pseudomembranous colitis in ischemic colitis secondary to methamphetamine use: a diagnostic challenge. Am J Gastroenterol. 2020;115:S889. doi: 10.14309/01. ajg.0000708940.76910.f0.
  13. Persons JE, Conway KS. Neuropathologic features in chronic methamphetamine use. Am J Forensic Med Pathol. 2023;44(2):77-82. doi: 10.1097/paf.0000000000000817.
  14. Manja V, Nrusimha A, Gao Y, Sheikh A, McGovern M, Heidenreich PA, et al. Methamphetamine-associated heart failure: a systematic review of observational studies. Heart. 2023;109(3):168-77. doi: 10.1136/heartjnl-2022-321610.
  15. Darke S, Kaye S, McKetin R, Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2008;27(3):253-62. doi: 10.1080/09595230801923702.
  16. Feelemyer JP, Richard E, Khan MR, Scheidell JD, Caniglia EC, Manandhar-Sasaki P, et al. Does the association between stimulant use and high-risk sexual behavior vary by injection drug use, sexual minority status, or HIV infection status? A meta-analysis. AIDS Behav. 2023;27(9):2883-90. doi: 10.1007/s10461-023-04012-4.
  17. Jan SU, Alam H, Khan A. Effects of methamphetamine withdrawal on the psychological and physiological condition of addicts. J Soc Sci Rev. 2022;2(3):138-44. doi: 10.54183/ jssr.v2i3.90.
  18. Kaka G, Rahmanzade R, Safee F, Haghparast A. Naloxone induces frequent jumping after chronic morphine and methamphetamine co-administration in rats. Basic Clin Neurosci. 2014;5(1):42-7.
  19. Kamali M, Tajadini H, Mehrabani M, Moghadari M. Consequences of opioid abuse and their treatments in Persian medicine: a review study. Addict Health. 2020;12(1):46-57. doi: 10.22122/ahj.v12i1.250.
  20. Kamali M, Kamali H, Doustmohammadi M, Sheikhbardsiri H, Moghadari M. Treatment of opium addiction in Persian medicine: a review study. J Educ Health Promot. 2021;10:157. doi: 10.4103/jehp.jehp_5_21.
  21. Batiha GE, Olatunde A, El-Mleeh A, Hetta HF, Al-Rejaie S, Alghamdi S, et al. Bioactive compounds, pharmacological actions, and pharmacokinetics of wormwood (Artemisia absinthium). Antibiotics (Basel). 2020;9(6):353. doi: 10.3390/ antibiotics9060353.
  22. Sharopov FS, Sulaimonova VA, Setzer WN. Composition of the essential oil of Artemisia absinthium from Tajikistan. Rec Nat Prod. 2012;6(2):127-34.
  23. Benkhaled A, Boudjelal A, Napoli E, Baali F, Ruberto G. Phytochemical profile, antioxidant activity and wound healing properties of Artemisia absinthium essential oil. Asian Pac J Trop Biomed. 2020;10(11):496-504. doi: 10.4103/2221- 1691.294089.
  24. Wubuli A, Abdulla R, Zhao J, Wu T, Aisa HA. Exploring anti-inflammatory and antioxidant-related quality markers of Artemisia absinthium based on spectrum-effect relationship. Phytochem Anal. 2024;35(5):1152-73. doi: 10.1002/ pca.3350.
  25. Bhat MM, Ansari AP, Ahmad A, Qayoom I, Reshi BM. Antipyretic activity of the hydro-alcoholic extract of Artemisia absinthium as a standalone and as an adjuvant with barley water against yeast-induced pyrexia in albino Wistar rats. J Complement Integr Med. 2024;21(1):46-52. doi: 10.1515/ jcim-2023-0307.
  26. Ivanescu B, Corciova A, Vlase L, Gheldiu AM, Miron A, Ababei DC, et al. Analgesic and anti-inflammatory activity of Artemisia extracts on animal models of nociception. Balneo PRM Res J. 2021;12(1):34-9.
  27. Rahimi M, Marefati N, Beheshti F, Ahmadabady S, Rakhshandeh H, Hosseini M. The effects of Artemisia absinthium on scopolamine-induced learning and memory impairment and brain tissue oxidative damage in adult rats. Avicenna J Phytomed. 2023;13(1):70-84. doi: 10.22038/ ajp.2022.62851.2991.
  28. Saberi A, Sepehri G, Safi Z, Razavi B, Jahandari F, Divsalar K, et al. Effects of methamphetamine on testes histopathology and spermatogenesis indices of adult male rats. Addict Health. 2017;9(4):199-205.
  29. Wang ZY, Guo LK, Han X, Song R, Dong GM, Ma CM, et al. Naltrexone attenuates methamphetamine-induced behavioral sensitization and conditioned place preference in mice. Behav Brain Res. 2021;399:112971. doi: 10.1016/j. bbr.2020.112971.
  30. Baslam A, Aitbaba A, Lamrani Hanchi A, Tazart Z, Aboufatima R, Soraa N, et al. Modulation of gut microbiome in ecstasy/ MDMA-induced behavioral and biochemical impairment in rats and potential of post-treatment with Anacyclus pyrethrum aqueous extract to mitigate adverse effects. Int J Mol Sci. 2023;24(10):9086. doi: 10.3390/ijms24109086.
  31. Brust JC. Abused agents: acute effects, withdrawal, and treatment. Continuum (Minneap Minn). 2004;10(5):14-47. doi: 10.1212/01.CON.0000293607.14958.c3.
  32. Taracha E, Czarna M, Turzyńska D, Maciejak P. Amphetamine-induced prolonged disturbances in tissue levels of dopamine and serotonin in the rat brain. Pharmacol Rep. 2023;75(3):596- 608. doi: 10.1007/s43440-023-00472-6.
  33. Hashem-Dabaghian F, Kianbakht S. A randomized controlled trial on the seeds of Sophora alopecuroides alopecuroides for the treatment of acute heroin withdrawal syndrome. Complement Ther Clin Pract. 2023;51:101740. doi: 10.1016/j. ctcp.2023.101740.
  34. Rezaeian L, Kalalian-Moghaddam H, Mohseni F, Khaksari M, Rafaiee R. Effects of berberine hydrochloride on methamphetamine-induced anxiety behaviors and relapse in rats. Iran J Basic Med Sci. 2020;23(11):1480-8. doi: 10.22038/ ijbms.2020.47285.10884.
  35. Koo BS, Kwon TS, Kim CH. Salviae miltiorrhizae Radix inhibits superoxide generation by activated rat microglias and mimics the action of amphetamine on in vitro rat striatal dopamine release. Neurochem Res. 2004;29(10):1837-45. doi: 10.1023/b:nere.0000042210.72927.ec.
  36. Thongsaard W, Marsden CA. A herbal medicine used in the treatment of addiction mimics the action of amphetamine on in vitro rat striatal dopamine release. Neurosci Lett. 2002;329(2):129-32. doi: 10.1016/s0304-3940(02)00658-4.
  37. Konrath EL, Arbo MD, Arbo BD, Hort MA, Elisabetsky E, Leal MB. Plants with anti-addictive potential. Adv Exp Med Biol. 2021;1308:185-215. doi: 10.1007/978-3-030-64872-5_14.
  38. Ali M, Abbasi BH, Ihsan-Ul-Haq M. Production of commercially important secondary metabolites and antioxidant activity in cell suspension cultures of Artemisia absinthium Ind Crops Prod. 2013;49:400-6. doi: 10.1016/j.indcrop.2013.05.033.
  39. Kharoubi O, Slimani M, Aoues A. Neuroprotective effect of wormwood against lead exposure. J Emerg Trauma Shock. 2011;4(1):82-8. doi: 10.4103/0974-2700.76834.
  40. Bora KS, Sharma A. Neuroprotective effect of Artemisia absinthium on focal ischemia and reperfusion-induced cerebral injury. J Ethnopharmacol. 2010;129(3):403-9. doi: 10.1016/j.jep.2010.04.030.
  41. Bora KS, Sharma A. Evaluation of antioxidant and free-radical scavenging potential of Artemisia absinthium. Pharm Biol. 2011;49(12):1216-23. doi: 10.3109/13880209.2011.578142.
  42. Craciunescu O, Constantin D, Gaspar A, Toma L, Utoiu E, Moldovan L. Evaluation of antioxidant and cytoprotective activities of Arnica montana and Artemisia absinthium L. ethanolic extracts. Chem Cent J. 2012;6(1):97. doi: 10.1186/1752-153x-6-97.
  43. Ahmad F, Khan RA, Rasheed S. Study of analgesic and anti-inflammatory activity from plant extracts of Lactuca scariola and Artemisia absinthium. J Islam Acad Sci. 1992;5(2):111–4.
  44. Nalbantsoy A, Erel SB, Köksal C, Göçmen B, Yıldız MZ, Karabay Yavaşoğlu N. Viper venom induced inflammation with Montivipera xanthina (Gray, 1849) and the anti-snake venom activities of Artemisia absinthium in rat. Toxicon. 2013;65:34-40. doi: 10.1016/j.toxicon.2012.12.017.
  45. Khattak SG, Gilani SN, Ikram M. Antipyretic studies on some indigenous Pakistani medicinal plants. J Ethnopharmacol. 1985;14(1):45-51. doi: 10.1016/0378-8741(85)90027-3.
  46. Zeraati F, Esna-Ashari F, Araghchian M, Emam AH, Vafaei Rad M, Seif S, et al. Evaluation of topical antinociceptive effect of Artemisia absinthium extract in mice and possible mechanisms. Afr J Pharm Pharmacol. 2014;8(19):492-6. doi: 10.5897/ajpp2012.1518.
  47. Basiri Z, Zeraati F, Esna-Ashari F, Mohammadi F, Razzaghi K, Araghchian M, et al. Topical effects of Artemisia absinthium ointment and liniment in comparison with piroxicam gel in patients with knee joint osteoarthritis: a randomized double-blind controlled trial. Iran J Med Sci. 2017;42(6):524-31.
  48. Beigh YA, Ganai AM. Potential of wormwood (Artemisia absinthium ) herb for use as additive in livestock feeding: a review. Pharma Innov. 2017;6(8 Pt C):176-87.
Addiction & Health
Volume 17
Pages 1-7

Files

Share

How to cite

Statistics